Concord Drugs Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 605306,
    "name": "Concord Drugs",
    "stock_name": "Concord Drugs",
    "full_name": "Concord Drugs Ltd",
    "name_url": "stocks-analysis/concord-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "76.62",
    "chg": -1.31,
    "chgp": "-1.68%",
    "dir": -1,
    "prev_price": "77.93",
    "mcapval": "100.95 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538965,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE858L01010",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "3.79 k",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/concord-drugs-605306-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "When is the next results date for Concord Drugs Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-concord-drugs-ltd-3999659",
        "imagepath": "",
        "date": "2026-05-19 23:17:25",
        "description": "The next results date for Concord Drugs Ltd is scheduled for 27 May 2026...."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3989182",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ConcordDrugsLtd_mojoScore_3989182.png",
        "date": "2026-05-13 10:11:11",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts Signal Elevated Price Risk Amidst Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-signal-elevated-price-risk-amidst-strong-returns-3958273",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordDrugsLtd_valuationdot_3958273.png",
        "date": "2026-04-23 08:00:44",
        "description": "Concord Drugs Ltd has seen a marked shift in its valuation parameters, moving from fair to expensive territory, prompting a downgrade in its investment grade. With a price-to-earnings (P/E) ratio soaring to 200.86 and price-to-book value (P/BV) at 3.33, investors are urged to reassess the stock’s price attractiveness amid sector peers and historical benchmarks."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3955792",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordDrugsLtd_mojoScore_3955792.png",
        "date": "2026-04-21 10:10:33",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts to Fair Amidst Elevated Price Multiples",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-to-fair-amidst-elevated-price-multiples-3948045",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordDrugsLtd_valuationdot_3948045.png",
        "date": "2026-04-16 08:00:52",
        "description": "Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating, driven primarily by a steep rise in its price-to-earnings (P/E) ratio and price-to-book value (P/BV). This change comes amid a mixed performance in the pharmaceuticals sector and raises questions about the stock’s price attractiveness relative to its peers and historical benchmarks."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3941407",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordDrugsLtd_mojoScore_3941407.png",
        "date": "2026-04-10 10:10:57",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3923728",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ConcordDrugsLtd_mojoScore_3923728.png",
        "date": "2026-03-30 10:10:31",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      }
    ],
    "total": 15,
    "sid": "605306",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/concord-drugs-605306"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Jun-2026",
      "details": "Copy of Newspaper publication for audited results for year ended 31st March2026.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "29-May-2026",
      "details": "Annual Secretarial Compliance report under Regulation 24(A)",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For Year Ending 31St March2026",
      "datetime": "29-May-2026",
      "details": "Financial Results for Year ending 31st March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

When is the next results date for Concord Drugs Ltd?

2026-05-19 23:17:25

The next results date for Concord Drugs Ltd is scheduled for 27 May 2026....

Concord Drugs Ltd is Rated Sell

2026-05-13 10:11:11

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd Valuation Shifts Signal Elevated Price Risk Amidst Strong Returns

2026-04-23 08:00:44

Concord Drugs Ltd has seen a marked shift in its valuation parameters, moving from fair to expensive territory, prompting a downgrade in its investment grade. With a price-to-earnings (P/E) ratio soaring to 200.86 and price-to-book value (P/BV) at 3.33, investors are urged to reassess the stock’s price attractiveness amid sector peers and historical benchmarks.

Concord Drugs Ltd is Rated Sell

2026-04-21 10:10:33

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd Valuation Shifts to Fair Amidst Elevated Price Multiples

2026-04-16 08:00:52

Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating, driven primarily by a steep rise in its price-to-earnings (P/E) ratio and price-to-book value (P/BV). This change comes amid a mixed performance in the pharmaceuticals sector and raises questions about the stock’s price attractiveness relative to its peers and historical benchmarks.

Concord Drugs Ltd is Rated Sell

2026-04-10 10:10:57

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd is Rated Sell

2026-03-30 10:10:31

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with the latest insights into the company’s performance and outlook.

View All News